We have previously reported the use of mini-pumps to provide continuous infusion of low-dose GM-CSF to the autologous NSCLC tumor cell vaccine site as an alternative to gene modification [23] and employed that strategy here. This evidence concerns the gene CSF2 and neoplasm.